J
Joseph J. Locascio
Researcher at Harvard University
Publications - 164
Citations - 11346
Joseph J. Locascio is an academic researcher from Harvard University. The author has contributed to research in topics: Dementia & Alzheimer's disease. The author has an hindex of 47, co-authored 147 publications receiving 9388 citations. Previous affiliations of Joseph J. Locascio include Case Western Reserve University & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease
Bin Zheng,Zhixiang Liao,Joseph J. Locascio,Kristen A. Lesniak,Sarah S. Roderick,Marla L. Watt,Aron Charles Eklund,Aron Charles Eklund,Yanli Zhang-James,Peter D. Kim,Michael A. Hauser,Edna Grünblatt,Linda B. Moran,Silvia Mandel,Peter Riederer,Renee M. Miller,Howard J. Federoff,Ullrich Wüllner,Spyridon Papapetropoulos,Moussa B.H. Youdim,Moussa B.H. Youdim,Ippolita Cantuti-Castelvetri,Anne B. Young,Jeffery M. Vance,Richard L. Davis,John C. Hedreen,Charles H. Adler,Thomas G. Beach,Manuel B. Graeber,Frank A. Middleton,Jean-Christophe Rochet,Clemens R. Scherzer,Clemens R. Scherzer +32 more
TL;DR: A genome-wide meta-analysis of gene sets (groups of genes that encode the same biological pathway or process) in 410 samples from patients with symptomatic Parkinson’s and subclinical disease and healthy controls identified 10 gene sets that were all associated with PD.
Journal ArticleDOI
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
Brit Mollenhauer,Brit Mollenhauer,Joseph J. Locascio,Walter J. Schulz-Schaeffer,Friederike Sixel-Döring,Claudia Trenkwalder,Michael G. Schlossmacher,Michael G. Schlossmacher +7 more
TL;DR: Although specificity was low, the high positive predictive value of CSF α-synuclein concentrations in patients presenting with synucleinopathy-type parkinsonism might be useful in stratification of patients in future clinical trials.
Journal ArticleDOI
Randomised controlled trials - the gold standard for effectiveness research: Study design: randomised controlled trials.
TL;DR: Learning points Randomised controlled trials are the reference standard for studying causal relationships between interventions and outcomes as randomisation eliminates much of the bias inherent with other study designs.
Journal ArticleDOI
Molecular markers of early Parkinson's disease based on gene expression in blood
Clemens R. Scherzer,Clemens R. Scherzer,Aron Charles Eklund,Lee Jae Morse,Zhixiang Liao,Joseph J. Locascio,Daniel Fefer,Michael A. Schwarzschild,Michael G. Schlossmacher,Michael A. Hauser,Jeffery M. Vance,Lewis Sudarsky,David G. Standaert,John H. Growdon,Roderick V. Jensen,Steven R. Gullans +15 more
TL;DR: Gene expression signals measured in blood can facilitate the development of biomarkers for PD, and the molecular multigene marker here identified is associated with risk of PD in 66 samples of the training set comprising healthy and disease controls.
Journal ArticleDOI
Imaging amyloid deposition in Lewy body diseases
Stephen N. Gomperts,Dorene M. Rentz,Erin K. Moran,John A. Becker,Joseph J. Locascio,William E. Klunk,Chet Mathis,David R. Elmaleh,Timothy M. Shoup,Alan J. Fischman,Bradley T. Hyman,John H. Growdon,Keith A. Johnson +12 more
TL;DR: Global cortical amyloid burden is high in dementia with Lewy bodies (DLB) but low in Parkinson disease dementia, and data suggest that β-amyloid may contribute selectively to the cognitive impairment of DLB and may contribute to the timing of dementia relative to the motor signs of parkinsonism.